HGH (191AA) Guide: Dosage, IU Conversion & Growth Hormone Breakdown
HGH (191AA)
HGH (191AA), also called somatropin, is recombinant human growth hormone made to match the 191-amino-acid sequence of natural human GH. FDA-approved somatropin products are used for specific growth hormone deficiency and related medical conditions, while performance, anti-aging, and body-composition use falls outside approved indications.
How It Works
Exogenous Growth Hormone → GH Receptor Activation → IGF-1 Production ↑ → Growth + Metabolic Signaling
HGH acts as growth hormone itself rather than stimulating the pituitary to release more GH. It activates growth hormone receptors and increases downstream IGF-1 production, influencing growth, protein metabolism, glucose regulation, fluid balance, and body-composition pathways.
Important Distinction
HGH is not a peptide in the same way smaller research peptides are commonly discussed.
It is a full 191-amino-acid recombinant human growth hormone that directly provides GH rather than stimulating endogenous GH release.
Because it can affect IGF-1, glucose, water retention, and endocrine signaling, monitoring matters more than with many smaller peptides.
FDA-approved somatropin products have product-specific concentrations, diluents, devices, and storage instructions.
Research-vial reconstitution should not be assumed to match the formulation or handling instructions of an approved somatropin product.
HGH Research Protocol
10 mg vial (~30 IU) + 3.0 mL BAC Water → 1 unit = 0.1 IU → Gradual Long-Term GH Support
Research Standard / Gradual Approach
10 mg vial (~30 IU) reconstituted with 3.0 mL bacteriostatic water
1 unit = 0.1 IU
IU conversion:
Somatropin is commonly converted at approximately 3 IU per mg, so 10 mg is approximately 30 IU. Actual product concentration and delivered volume depend on the specific formulation and diluent.
Somatropin is commonly converted at approximately 3 IU per mg, so 10 mg is approximately 30 IU. Actual product concentration and delivered volume depend on the specific formulation and diluent.
Week 1–2
Lower Discussed Range
Dose1 IU daily
Units10 units
FrequencyOnce daily
Week 3–6
Adjustment Range
Dose2 IU daily
Units20 units
FrequencyOnce daily
Week 7+
Higher Community-Discussed Range
Dose2–4 IU daily
Units20–40 units
FrequencyOnce daily or split dosing
Important dosing distinction:
FDA-approved somatropin treatment does not use one universal 1 IU → 2 IU → 2–4 IU progression. Clinical dosing is indication-specific and individualized. The framework reflects commonly discussed non-clinical/community use rather than an FDA-approved treatment schedule.
FDA-approved somatropin treatment does not use one universal 1 IU → 2 IU → 2–4 IU progression. Clinical dosing is indication-specific and individualized. The framework reflects commonly discussed non-clinical/community use rather than an FDA-approved treatment schedule.
Simple structure:
HGH is usually approached gradually because water retention, joint stiffness, carpal tunnel-like symptoms, and glucose changes can be dose-dependent. A slow build makes response easier to monitor.
HGH is usually approached gradually because water retention, joint stiffness, carpal tunnel-like symptoms, and glucose changes can be dose-dependent. A slow build makes response easier to monitor.
How to Use HGH (Cycle, Timing & Injection)
Research FrequencyOnce daily or split dosing
Research TimingMorning fasted or before bed
Research RouteSubcutaneous
Research Cycle Length8–24+ weeks
Use StyleLonger-term compound
Best Time to Use Research Frame-work
Morning fasted use is commonly discussed when fat-loss support is the main goal.
Before-bed use is often discussed when recovery and sleep support are the focus.
Higher ranges may be split into more than one dose for comfort and steadier exposure.
Consistent daily use typically matters more than changing timing frequently.
Where to Inject Research Frame-work
Subcutaneous injection is commonly discussed.
Common sites include abdomen, thigh, or upper arm.
Rotate injection sites regularly to reduce irritation.
When to Use Research Frame-work
During longer recovery-focused phases
During body composition or fat-metabolism support phases
When sleep, tissue repair, or IGF-1-mediated effects are the research focus
As a longer-term structured protocol rather than a short quick cycle
Simple Strategy
Start Low
HGH is best approached gradually because side effects are often related to dose and duration.
Monitor Response
Track water retention, sleep, soreness, body composition, glucose response, and IGF-1-related markers when relevant.
Clinical Use vs Community Use
Clinical / Prescription Use
CompoundSomatropin
StatusFDA-approved for specific indications
DoseIndividualized by indication, response, and IGF-1
MonitoringIGF-1, glucose, adverse effects, and condition-specific markers
Community / Performance Discussion
Commonly Discussed Range1–4 IU daily
Evidence StatusNot an FDA-approved body-composition protocol
Research Frame-work Reconstitution & Dosing
Example Research-Vial Reconstitution & IU Math
Vial10 mg (~30 IU)
Water3.0 mL
Concentration10 IU/mL
Conversion1 unit = 0.1 IU
Dose Reference
10 units = 1 IU
20 units = 2 IU
30 units = 3 IU
40 units = 4 IU
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly into vial or down the vial wall
Gently swirl, do not shake
Allow powder to fully dissolve before use
Refrigerate after reconstitution
Important:
Unit math depends on vial size and water volume. This example uses a 10 mg vial, estimated around 30 IU, with 3.0 mL added, creating a clean 1 unit = 0.1 IU conversion.
Unit math depends on vial size and water volume. This example uses a 10 mg vial, estimated around 30 IU, with 3.0 mL added, creating a clean 1 unit = 0.1 IU conversion.
Important formulation distinction:
FDA-approved somatropin products should be prepared only with the manufacturer-supplied system or diluent. The 10 mg + 3.0 mL example is a research-vial math example and should not be applied to branded prescription somatropin products.
FDA-approved somatropin products should be prepared only with the manufacturer-supplied system or diluent. The 10 mg + 3.0 mL example is a research-vial math example and should not be applied to branded prescription somatropin products.
Research Frame-work Storage & Shelf Life
Storage & Shelf Life
Lyophilized (unmixed)
Refrigerated (2–8°C): ~12–24 months
Frozen (−20°C): up to ~2–3 years
Store sealed, dry, and protected from light
Reconstituted (mixed)
Refrigerated (2–8°C): about 2–4 weeks typical use window
Do not freeze after mixing
Avoid repeated temperature changes
Best Practice
Handling
Keep HGH cold, protected from light, and limit unnecessary handling.
Visual Check
If the solution becomes cloudy, discolored, or contains visible particles, it is safer not to continue using it.
Best practice:
HGH formulations are not interchangeable. Product-specific storage and preparation instructions should take priority over general peptide handling rules.
HGH formulations are not interchangeable. Product-specific storage and preparation instructions should take priority over general peptide handling rules.
Prescription Somatropin
Follow the exact storage instructions provided with the specific branded product.
Different somatropin products use different cartridges, preservatives, diluents, and post-reconstitution storage windows.
Do not substitute generic peptide-storage timelines for manufacturer labeling.
Research Frame-work Time Between Cycles
GH Therapy / Research Exposure → Monitor IGF-1 + Metabolic Response → Adjust or Continue
Research Standard Time Between Cycles
Cycle Length8–24+ weeks
Review PointEvery 8–12 weeks
Time OffOften 4–8+ weeks depending on goals and response
Why this is different:
\ HGH is usually discussed as a longer-term hormone-based compound rather than a short peptide cycle. Time off or adjustment is usually based on response, bloodwork, glucose markers, water retention, side effects, and whether the original goal is still active.
\ HGH is usually discussed as a longer-term hormone-based compound rather than a short peptide cycle. Time off or adjustment is usually based on response, bloodwork, glucose markers, water retention, side effects, and whether the original goal is still active.
Research Frame-work Best Ways to Structure It
Option 18–12 weeks on, reassess
Useful for shorter body composition or recovery-support phases
Option 212–24+ weeks with monitoring
More common for longer-term hormone-style protocols
Option 3Use until goal phase ends, then take time off
Best when paired with a clear recovery, body composition, or clinical-style monitoring goal
When to Stop or Adjust Sooner
Water retention becomes excessive
Carpal tunnel-like symptoms or joint stiffness become noticeable
Blood sugar trends worsen
IGF-1 rises beyond the intended range
You are continuing without a clear goal or monitoring plan
Community / Research Framework
8–24 week phases are commonly discussed outside clinical treatment.
There is no evidence-based rule requiring a 4–8 week break after a body-composition-focused HGH phase.
Longer exposure makes metabolic and IGF-1 monitoring increasingly important.
Monitoring During Use
IGF-1 levels
Fasting glucose and HbA1c when appropriate
Fluid retention or edema
Joint stiffness or carpal tunnel-like symptoms
Blood pressure
Body composition and clinical response
Thyroid and other endocrine markers when clinically indicated
Benefits
FDA-approved replacement therapy for specific growth hormone deficiency and related conditions
Increases GH receptor signaling and downstream IGF-1 production
Can influence body composition, protein metabolism, and fat metabolism
Clinical benefits depend on the underlying indication and appropriate dosing
Potential Side Effects
Edema and fluid-related symptoms
Headache
Potential worsening of insulin resistance or glucose intolerance
Excessive exposure can produce signs associated with growth hormone excess
Important Notes
HGH 191AA is recombinant human growth hormone, commonly called somatropin.
Somatropin is FDA-approved for specific medical indications, but not for general anti-aging, bodybuilding, or fat-loss use.
Prescription somatropin products have product-specific concentrations, diluents, devices, and storage instructions.
Community IU dosing frameworks should not be confused with indication-specific clinical dosing.
IGF-1, glucose regulation, fluid retention, and other endocrine effects are important monitoring considerations.
Excessive or prolonged GH exposure can produce clinically significant adverse effects.
Important Disclaimer
Somatropin (recombinant human growth hormone) is FDA-approved for specific prescription indications. It is not FDA-approved for general bodybuilding, anti-aging, or cosmetic fat-loss use. Community dosing and research-vial protocols should not be confused with approved product labeling or individualized medical treatment. This content is for educational purposes only.
Research & References
Primary Research
- Salomon F, Cuneo RC, Hesp R, Sönksen PH. The Effects of Treatment with Recombinant Human Growth Hormone on Body Composition and Metabolism in Adults with Growth Hormone Deficiency. New England Journal of Medicine. 1989;321(26):1797-1803.
- Bengtsson BA, Edén S, Lönn L, et al. Treatment of Adults with Growth Hormone (GH) Deficiency with Recombinant Human GH. Journal of Clinical Endocrinology & Metabolism. 1993;76(2):309-317.
- Hoffman AR, Kuntze JE, Baptista J, et al. Growth Hormone Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial. Journal of Clinical Endocrinology & Metabolism. 2004;89(5):2048-2056.
Reviews & Supporting Research
- Baum HB, Biller BMK, Finkelstein JS, et al. Effects of Physiologic Growth Hormone Therapy on Bone Density and Body Composition in Patients with Adult-Onset Growth Hormone Deficiency: A Randomized, Placebo-Controlled Trial. Annals of Internal Medicine. 1996;125(11):883-890.
- Gibney J, Wallace JD, Spinks T, et al. The Effects of 10 Years of Recombinant Human Growth Hormone (GH) in Adult GH-Deficient Patients. Journal of Clinical Endocrinology & Metabolism. 1999;84(8):2596-2602.
Research Note: The clinical trials above establish the safety and efficacy profile of recombinant human growth hormone in confirmed GH-deficient adults under medical supervision. Self-administered dosing protocols for anti-aging, body composition, or performance purposes described on this page extrapolate from this clinical literature and are not themselves the subject of the cited trials.
Comments
Post a Comment